Celcuity (NASDAQ:CELC) Downgraded to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Celcuity (NASDAQ:CELC) from a sell rating to a strong sell rating in a research report report published on Saturday.

Several other analysts have also recently commented on the company. Craig Hallum reiterated a “buy” rating and issued a $178.00 target price on shares of Celcuity in a report on Wednesday, July 15th. Weiss Ratings upgraded shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. Wells Fargo & Company lowered their price target on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a report on Wednesday, June 3rd. Citigroup restated an “outperform” rating on shares of Celcuity in a research report on Wednesday, July 15th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Celcuity in a research note on Wednesday, June 3rd. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $153.64.

Celcuity Trading Up 6.2%

NASDAQ CELC opened at $92.00 on Friday. The business’s 50-day moving average price is $93.88 and its two-hundred day moving average price is $108.45. Celcuity has a 12 month low of $44.42 and a 12 month high of $151.02. The firm has a market capitalization of $4.49 billion, a PE ratio of -21.40 and a beta of 0.20. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.28). On average, analysts expect that Celcuity will post -3.76 EPS for the current year.

Institutional Investors Weigh In On Celcuity

Several large investors have recently added to or reduced their stakes in CELC. Parallel Advisors LLC bought a new stake in Celcuity in the first quarter worth approximately $38,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after buying an additional 319 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Celcuity during the 4th quarter valued at $42,000. PNC Financial Services Group Inc. lifted its position in shares of Celcuity by 20.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock valued at $59,000 after acquiring an additional 86 shares during the period. Finally, KBC Group NV bought a new position in Celcuity during the first quarter worth $64,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Key Celcuity News

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $155 price target, implying substantial upside from the recent $92 share price. The endorsement reinforces bullish sentiment following Celcuity’s regulatory and commercial progress. Benzinga analyst rating report
• Positive Sentiment: An analyst report maintained a Buy view, citing REVTORPYK/gedatolisib’s FDA approval and rapid NCCN Category 1 inclusion as factors that reduce clinical and adoption risk. Strong VIKTORIA-1 results, including improved efficacy and tolerability, could support rapid physician uptake and a potential blockbuster franchise. Celcuity also reported approximately $754 million in cash, providing funding visibility through 2029 despite elevated launch spending. Celcuity: REVTORPYK Is Now A Commercial Story
• Neutral Sentiment: Stifel Nicolaus maintained a Buy rating but reduced its price target from $175 to $150, while Needham kept a Buy rating and lowered its target from $157 to $140. Both firms remain bullish, but the cuts indicate more cautious near-term assumptions. Benzinga analyst rating reports
• Negative Sentiment: Celcuity’s second-quarter results highlighted commercialization-related financial pressure. The company reported a $1.44 per-share loss, wider than the $1.16 consensus loss, and revenue of only $0.09 million versus the $4.42 million estimate. The results and increased launch-related SG&A prompted analysts to reduce forecasts, although the company’s cash balance provides a substantial operating runway. Celcuity second-quarter 2026 results

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.